We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

FDA Clears Diagnostic Assay for Group B Strep

By LabMedica International staff writers
Posted on 10 Aug 2018
Print article
Image: The NeuMoDx GBS assay is run on the 288 molecular system (Photo courtesy of NeuMoDx Molecular).
Image: The NeuMoDx GBS assay is run on the 288 molecular system (Photo courtesy of NeuMoDx Molecular).
Group B Streptococcus (GBS) is a Gram-positive bacterium found in 10% to 35% of healthy adults and is a commonly found bacterium within the human body. A person who carries GBS and does not present symptoms of GBS disease is said to be “colonized” with GBS.

GBS colonization is not considered contagious, however, under certain circumstances, GBS can invade the body and cause serious infection; this is referred to as Group B Streptococcal disease. It is a leading cause of life-threatening bacterial infection in newborns who acquire the disease during birth by vertical (mother-to-baby) transmission. Approximately 2,000 cases of newborn infections occur per year, with estimates of a mortality rate of 0.27 per 1,000 live births.

The US Food and Drug Administration (FDA, Silver Springs, MD, USA) have granted 510(k) clearance to a high-throughput molecular diagnostics platform and Group B Strep assay from NeuMoDx Molecular (Ann Arbor, MI, USA). The 288 Molecular System is an automated sample-to-answer diagnostics platform that runs up to 288 patient samples in continuous random-access mode. The time to first results is approximately one hour, according to the firm, with a walkaway window of more than six hours, and NeuMoDx intends the system to be used in central laboratories of hospitals and clinical reference laboratories.

Testing for GBS colonization is usually performed in the third trimester of pregnancy to prevent complications of transmission to a newborn during labor and delivery. The NeuMoDx GBS Assay is a qualitative polymerase chain reaction (PCR)-based diagnostic test to detect an 88 base-pair region of the pcsB gene and incorporates sample lysis, automated DNA extraction, and real-time PCR. The firm said the assay showed a sensitivity of 97% and specificity of 96% compared to culture in a multicenter clinical performance study.

The revolutionary dry format reagents require no refrigeration and are extremely robust with an on-board stability of greater than 60 days, and ambient temperature storage shelf life of greater than one year. Additionally, the unitized format of the dry reagents significantly increases operating efficiency while minimizing the waste associated with systems requiring manual reconstitution and/or use of bulk format lyophilized reagents.

Related Links:
US Food and Drug Administration
NeuMoDx Molecular

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.